← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Siteone Therapeutics, Inc.
South San Francisco, CA
$21,684,664
Total funding
12
Grants
Funding over time
peak $5.3M · FY2013–23$10M$7.5M$5M$2.5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$20,680,397 · 11
DOD$1,004,267 · 1
By mechanism
UG3$10,719,732 · 2
R44$7,748,116 · 4
U44$1,143,705 · 1
R43$1,068,844 · 4
—$1,004,267 · 1
Investigators at Siteone Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Largest grants
Development of a Potent and Selective Nav1.8 inhibitor for the Treatment of Acute and Chronic Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders$5,341,667
UG3 · FY2023 · DA
Development of a Potent and Highly Selective NaV1.7 Inhibitor for the Treatment of Acute Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders$2,937,963
UG3 · FY2019 · DA
Development of a Potent and Highly Selective NaV1.7 Inhibitor for the Treatment of Acute Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders$2,440,102
UG3 · FY2020 · DA
Development of a Selective Inhibitor of NaV1.7 for the Treatment of Ocular Pain$1,081,115
R44 · FY2021 · EY
Development of Nav1.7 Selective Inhibitors for the Treatment of Chronic Cough$1,055,826
R44 · FY2022 · HL
IND-ENABLING DEVELOPMENT OF SELECTIVE INHIBITORS OF NAV1.7$1,004,267
· FY2017 · Department of the Army
GUANIDINIUM DERIVATIVES FOR THE TREATMENT OF OCULAR PAIN$888,892
R44 · FY2019 · EY
Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain$829,314
R44 · FY2017 · NS
Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain$756,321
R44 · FY2015 · NS
Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain$681,135
R44 · FY2014 · NS
Development of Nav1.7 Selective Inhibitors for the Treatment of Chronic Cough$677,568
R44 · FY2021 · HL
Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain$616,855
R44 · FY2016 · NS
GUANIDINIUM DERIVATIVES FOR THE TREATMENT OF OCULAR PAIN$601,128
R44 · FY2018 · EY
Development of a Selective Inhibitor of NaV1.7 for the Treatment of Ocular Pain$559,962
R44 · FY2022 · EY
Discovery of NaV1.7 Inhibitors for the Treatment of Pain$461,907
U44 · FY2020 · NS
Discovery of NaV1.7 Inhibitors for the Treatment of Pain$455,622
U44 · FY2021 · NS
Development of NaV1.7 Inhibitors for the Treatment of Chronic Cough$323,733
R43 · FY2019 · HL
Evaluation of Sodium Channel Inhibitors as Therapeutics for Chronic Muscle Disord$285,048
R43 · FY2013 · GM
Design, Synthesis and Evaluation of Novel Isoform-Selective Sodium Channel Inhibi$236,235
R43 · FY2013 · NS
Discovery of NaV1.7 Inhibitors for the Treatment of Pain$226,176
U44 · FY2019 · NS